Analysts think CRSP stock price could increase by 115%
Apr 10, 2025, 11:25 AM
2.27%
What does CRSP do
CRISPR Therapeutics AG, headquartered in Zug, develops gene-based medicines for serious diseases using its CRISPR/Cas9 platform and went public on October 19, 2016. The company focuses on gene editing to treat genetically-defined diseases and enhance cellular therapies.
26 analysts think CRSP stock price will increase by 115.18%. The current median analyst target is $74.97 compared to a current stock price of $34.84. The lowest analysts target is $32.32 and the highest analyst target is $281.40.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.